Cancer Treatment Today

Amrubicin, previously known as SM-5887, is an anthracycline used in the treatment of lung cancer. It is marketed in Japan since 2002 by Sumitomo Pharmaceuticals under the brand name Calsed. Two phase 2 studies of amrubicin in Japanese populations with previously treated SCLC have shown impressive results. Amrubicin has been granted Fast Track product designation by the U.S. Food and Drug Administration (FDA) for the treatment of small cell lung cancer after first-line chemotherapy.
Amrubicin is being studied in clicnal trials and there are currenlty seven such trials ongoing (http://clinicaltrials.gov/ct2/results?term=amrubicin)